Antiviral therapy for hepatitis C is associated with improved clinical outcomes in patients with advanced fibrosis

Expert Review of Gastroenterology and Hepatology

Volumn 4, Issue 5, 2010, Pages 535-539

  Russo, Mark W ^a  

^a CAROLINAS MEDICAL CENTER   (United States)

Author keywords

antiviral therapy; carcinogenesis; cirrhosis; hepatitis C; hepatocellular carcinoma; interferon; liver cancer; prevention

Indexed keywords

ALPHA INTERFERON; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; DRUG RESPONSE; FEMALE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NOTE; STOMACH HEMORRHAGE; TREATMENT OUTCOME;

EID: 77958040548     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.10.60     Document Type: Note

References (21)

1. Cardosa AC, Moucari R, Figueiredo-Mendes C et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: Incidence and survival in hepatitis C patients with advanced fibrosis. J. Hepatol. 52, 652-657 (2010).
2. Alazawi W, Cunningham M, Dearden J, Foster GR. Systematic review: Outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment. Phamracol. Ther. 32(3), 344-355 (2010).
3. Sangiovanni A, Prati GM, Fasani P et al. The natural history of compenstated cirrhosis due to hepatitis virus: A 17-year cohort study of 214 patients. Hepatology 43, 1303-1310 (2006).
4. Lok AS, Seeff LB, Morgan TR et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 136, 138-148 (2009). Data from a large prospective randomized trial on the incidence of hepatocellular carcinoma in hepatitis C patients with advanced fibrosis and cirrhosis.
5. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression. Gastroenterology 138(2), 513-521 (2010).
6. Veldt BJ, Heathcote J, Wedenmeyer H et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann. Intern. Med. 147, 677-684 (2007). One of the first studies demonstrating reduced risk of liver-related complications in hepatitis C virus (HCV) patients who achieve sustained virologic response (SVR), although a reduction of HCC was not seen.
7. Bruno S, Stroffolini T, Colombo M et al. Sustained virological response to interferon-α is associated with improved outcome in HCV-related cirrhosis: A retrospective study. Hepatology 45(3), 579-587 (2007).
8. Di Bisceglie AM, Shiffman ML, Everson GT et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N. Engl. J. Med. 359, 2429-2441 (2008).
9. Morgan TR, Ghany MG, Kim HY et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 52(3), 833-844 (2010). Results from the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial on the effect of SVR on clinical outcomes in patients with chronic HCV and advanced fibrosis/cirrhosis who achieve SVR demonstrating a reduction in liver-related complications.
10. El-Serag H, Rudolph L. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 132, 2557-3576 (2007).
11. Schulze-Krebs A, Preimel D, Popov Y et al. Hepatitis C virus-replicating hepatocytes induce fibrogenic activation of hepatic stellate cells. Gastroenterology 129, 246-248 (2005).
12. Matsuzaki K, Murata M, Yoshida K et al. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor signaling promoting cirrhosis and hepatocellular carcinoma. Hepatology 46, 48-57 (2007).
13. Moriye K, Fujiie H, Shintani Y et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat. Med. 4, 1065-1067 (1998).
14. McHutchison JG, Everson GT, Gordon SC et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 360, 1827-1838 (2009).
15. Kwo PY, Lawitz EJ, McCone J et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon α-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT-1): An open label, randomized, multicentre Phase II trial. Lancet (10), 60934-60938 (2010).
16. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008).
17. Khan F, Peltekian KM, Peterson TC. Effect of interferon-α, ribavirin, pentoxyphylline, and interleukin-18 antibody on hepatitis C sera-stimulated hepatic stellate cell proliferation. J. Interf. Cytokine Res. 28, 643-651 (2008).
18. Tasci I, Mas MR, Vural SR et al. Rat liver fibrosis regresses better with pegylated interferon α-2b and ursodeoxycholic acid treatments than spontaneous recovery. Liver Int. 26, 261-268 (2006).
19. Wang L, Wu WZ Sun HC et al. Mechanism of interferon a on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J. Gastrointest. Surg. 7, 587-594 (2003).
20. Cao B, Chen XP, Zhu P et al. Inhibitory effect of interferon-α-2b on expression of cyclooxygenase-2 and vascular endothelial growth factor in human hepatocellular carcinoma inoculated nude mice. World J. Gastroenterol. 14, 6802-6807 (2008).
21. Mazzeferro V, Romito R, Schiavo M et al. Prevention of hepatocellular carcinoma recurrence with a-interferon after liver resection in HCV cirrhosis. Hepatology 44, 1543-1554 (2006). Randomized clinical trial of interferon to prevent HCC recurrence, demonstrating reduction in HCC recurrence after resection in subgroups of patients.